Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Disease × Genitourinary × Clear all

Phase

Phase NA 34 Phase 2 6 Phase 3 3 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 65 Urinary Bladder Neoplasms 17 Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 5 Neoplasm Metastasis 4 Lung Neoplasms 4 Recurrence 3 Prostatic Neoplasms, Castration-Resistant 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma 3 Prostate CA 2 Pancreatic Neoplasms 2 Kidney Neoplasms 2 Kidney Failure, Chronic 2 Gallbladder Neoplasms 2 Critical Illness 2 Carcinoma in Situ 2 Agnosia 2 Acute Kidney Injury 2 Wilms Tumor 1 Virus Diseases 1 Venous Thromboembolism 1 Urothelial Carcinoma of the Renal Pelvis and Ureter 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urethral Neoplasms 1 Testicular Neoplasms 1

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02981368 2021-08-09

OSPREY

Progenics Pharmaceuticals, Inc.

Phase 2/3 Completed

385 enrolled 20 charts

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡